Page 485 - Small Caps News Today

Animoca Brands to publish and develop NFT-based ‘Crypto Space Commander’ game Crypto Space Commander utilises Ethereum blockchain to secure game assets and allows players to profit from their skills and wits in the vastness of space. The game allows players to travel to different star systems and mine stellar bodies for resources. Animoca Brands has entered into a publishing agreement with Lucid Sight to grant Animoca an exclusive and global license to publish and further devel...

Testing to date has shown that the Ultra Bright Domain, which consists of extremely high purity kaolinite with ultra-high brightness and with low...

The NC Protect platform is used for enhanced information protection for file access and sharing, messaging and emailing of sensitive and classified...

MNF Group Transforming Into Higher Growth 11:32 AM A refinement to the MNF Group business has been welcomed, with the opportunities in wholesale voice services now firmly in its sights -Post Direct sale, MNF Group becomes largely a wholesale services provider -Potential to be a leader in wholesale voice in Asia-Pacific -Brokers see a significant value opportunity opening up   By Eva Brocklehurst Several catalysts have combined for MNF Group ((MNF)) recently, and the companys latest announcemen...

The IP geophysical survey supports previously released ground magnetic results and also enhances the potential for Detroit to host multiple gold and...

A boost in Blue Star Helium’s Colorado landholding will better position the helium explorer and producer to carry out a drilling campaign.

The company will use the funds to expand and increase revenue streams, markets and value

The company is Westminster’s largest shareholder and is poised to leverage its South American copper assets as increased demand for the metal continues...

Noxopharm accelerates towards Phase 2 trial for DARRT-2 study of anti-cancer drug Veyonda® The Phase Two trial will broaden the scope of studies into a potential cancer treatment using a higher dose of its Veyonda® drug candidate. Veyonda® is an immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells Noxopharm Ltd (ASX:NOX) is gearing up for a Phase Two trial of its anti-cancer drug Veyonda® for its upcoming DARRT-2 study.  DARRT-2 will invol...

The board conducted the review to determine how to best optimise the value of the company’s Mexican mineral projects.